이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

A Study of Adalimumab in Japanese Subjects With Rheumatoid Arthritis

2012년 8월 1일 업데이트: Abbott

A Phase 3 Multi-Center, Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study Comparing Adalimumab and Placebo in Adult Japanese Subjects With Rheumatoid Arthritis

To evaluate the potential of adalimumab to inhibit radiographic progression in joint destruction compared with placebo in adult Japanese subjects with recent onset of rheumatoid arthritis.

연구 개요

상태

완전한

정황

류마티스 관절염

개입 / 치료

상세 설명

This was a Phase 3 multicenter, randomized, double-blind, parallel group, placebo-controlled study designed to evaluate the inhibition of radiographic progression by adalimumab compared with placebo in adult Japanese patients with early rheumatoid arthritis (RA) who had not been previously treated with methotrexate (MTX). Eligible participants were randomized 1:1 to receive either a subcutaneous injection of adalimumab 40 mg or matching placebo every other week (eow) during the 26-week double-blind phase. All participants also received 6 mg to 8 mg MTX weekly as basal treatment for their disease. Participants who experienced an increase in disease activity (more than 20% increase in tender joint count and swollen joint count) at Week 12, 16, or 20 compared with Baseline after having increased MTX dose to 8 mg per week for at least 4 weeks were discontinued from the double-blind phase and were eligible to receive open-label adalimumab 40 mg eow as rescue treatment. Participants who completed the 26 weeks of treatment (either double-blind study drug [adalimumab or placebo] treatment or open-label adalimumab treatment) were eligible to enter the 26-week open-label phase in which they received adalimumab 40 mg eow. Efficacy and safety assessments were performed at Baseline and at designated study visits.

연구 유형

중재적

등록 (실제)

334

단계

3단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 장소

일본
- - Anjo, 일본
    - Site Reference ID/Investigator# 46861
  - Aomori, 일본
    - Site Reference ID/Investigator# 46919
  - Chiba, 일본
    - Site Reference ID/Investigator# 46805
  - Chiba, 일본
    - Site Reference ID/Investigator# 46806
  - Chiba, 일본
    - Site Reference ID/Investigator# 46880
  - Chiba, 일본
    - Site Reference ID/Investigator# 46881
  - Fuchu, 일본
    - Site Reference ID/Investigator# 46890
  - Fukuoka, 일본
    - Site Reference ID/Investigator# 46902
  - Fukuoka, 일본
    - Site Reference ID/Investigator# 46903
  - Fukuoka, 일본
    - Site Reference ID/Investigator# 46904
  - Gifu, 일본
    - Site Reference ID/Investigator# 46856
  - Gunma, 일본
    - Site Reference ID/Investigator# 46944
  - Hiroshima, 일본
    - Site Reference ID/Investigator# 46893
  - Hiroshima, 일본
    - Site Reference ID/Investigator# 46894
  - Hokkaido, 일본
    - Site Reference ID/Investigator# 12161
  - Hokkaido, 일본
    - Site Reference ID/Investigator# 46916
  - Hokkaido, 일본
    - Site Reference ID/Investigator# 46918
  - Hyogo, 일본
    - Site Reference ID/Investigator# 46865
  - Hyogo, 일본
    - Site Reference ID/Investigator# 46871
  - Ibaraki, 일본
    - Site Reference ID/Investigator# 46801
  - Ibaraki, 일본
    - Site Reference ID/Investigator# 46925
  - Iwate, 일본
    - Site Reference ID/Investigator# 46800
  - Kagoshima, 일본
    - Site Reference ID/Investigator# 46873
  - Kagoshima, 일본
    - Site Reference ID/Investigator# 46874
  - Kanagawa, 일본
    - Site Reference ID/Investigator# 46845
  - Kanagawa, 일본
    - Site Reference ID/Investigator# 46899
  - Kanagawa, 일본
    - Site Reference ID/Investigator# 46901
  - Kanazawa, 일본
    - Site Reference ID/Investigator# 46851
  - Kanazawa, 일본
    - Site Reference ID/Investigator# 46852
  - Kawagoe, 일본
    - Site Reference ID/Investigator# 46802
  - Kawasaki, 일본
    - Site Reference ID/Investigator# 46900
  - Kirishima, 일본
    - Site Reference ID/Investigator# 46875
  - Kitakyushu, 일본
    - Site Reference ID/Investigator# 46870
  - Kumamoto, 일본
    - Site Reference ID/Investigator# 46872
  - Kumamoto, 일본
    - Site Reference ID/Investigator# 46912
  - Kyoto, 일본
    - Site Reference ID/Investigator# 46864
  - Maebashi, 일본
    - Site Reference ID/Investigator# 46943
  - Matsuyama, 일본
    - Site Reference ID/Investigator# 46898
  - Miyazaki, 일본
    - Site Reference ID/Investigator# 46915
  - Nagano, 일본
    - Site Reference ID/Investigator# 46853
  - Nagano, 일본
    - Site Reference ID/Investigator# 46855
  - Nagasaki, 일본
    - Site Reference ID/Investigator# 46909
  - Nagasaki, 일본
    - Site Reference ID/Investigator# 46910
  - Nagasaki, 일본
    - Site Reference ID/Investigator# 46911
  - Nagoya, 일본
    - Site Reference ID/Investigator# 46858
  - Nagoya, 일본
    - Site Reference ID/Investigator# 46860
  - Nara, 일본
    - Site Reference ID/Investigator# 46877
  - Nara, 일본
    - Site Reference ID/Investigator# 46885
  - Niigata, 일본
    - Site Reference ID/Investigator# 46848
  - Niigata, 일본
    - Site Reference ID/Investigator# 46906
  - Oita, 일본
    - Site Reference ID/Investigator# 46914
  - Okayama, 일본
    - Site Reference ID/Investigator# 46869
  - Okayama, 일본
    - Site Reference ID/Investigator# 46886
  - Okayama, 일본
    - Site Reference ID/Investigator# 46887
  - Okayama, 일본
    - Site Reference ID/Investigator# 46892
  - Okinawa, 일본
    - Site Reference ID/Investigator# 46876
  - Osaka, 일본
    - Site Reference ID/Investigator# 46946
  - Osaka, 일본
    - Site Reference ID/Investigator# 46947
  - Rifu, 일본
    - Site Reference ID/Investigator# 46842
  - Sagamihara, 일본
    - Site Reference ID/Investigator# 46846
  - Saitama, 일본
    - Site Reference ID/Investigator# 46803
  - Saitama, 일본
    - Site Reference ID/Investigator# 46804
  - Saitama, 일본
    - Site Reference ID/Investigator# 46878
  - Saitama, 일본
    - Site Reference ID/Investigator# 46879
  - Sapporo, 일본
    - Site Reference ID/Investigator# 46917
  - Shimotsuke, 일본
    - Site Reference ID/Investigator# 46942
  - Shizuoka, 일본
    - Site Reference ID/Investigator# 46854
  - Shizuoka, 일본
    - Site Reference ID/Investigator# 46857
  - Shizuoka, 일본
    - Site Reference ID/Investigator# 46859
  - Takamatsu, 일본
    - Site Reference ID/Investigator# 46895
  - Tokyo, 일본
    - Site Reference ID/Investigator# 46843
  - Tokyo, 일본
    - Site Reference ID/Investigator# 46844
  - Tokyo, 일본
    - Site Reference ID/Investigator# 46850
  - Tokyo, 일본
    - Site Reference ID/Investigator# 46882
  - Tokyo, 일본
    - Site Reference ID/Investigator# 46883
  - Tokyo, 일본
    - Site Reference ID/Investigator# 46884
  - Tokyo, 일본
    - Site Reference ID/Investigator# 46888
  - Tokyo, 일본
    - Site Reference ID/Investigator# 46889
  - Tokyo, 일본
    - Site Reference ID/Investigator# 46891
  - Tokyo, 일본
    - Site Reference ID/Investigator# 46896
  - Toyama, 일본
    - Site Reference ID/Investigator# 46849
  - Toyama, 일본
    - Site Reference ID/Investigator# 46907
  - Toyoake, 일본
    - Site Reference ID/Investigator# 46862
  - Toyohashi, 일본
    - Site Reference ID/Investigator# 46866
  - Tsu, 일본
    - Site Reference ID/Investigator# 46863
  - Tsukuba, 일본
    - Site Reference ID/Investigator# 46926
  - Yokohama, 일본
    - Site Reference ID/Investigator# 46897
  - Yokohama, 일본
    - Site Reference ID/Investigator# 46905

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

20년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria

Rheumatoid arthritis based on the American College of Rheumatology criteria
Methotrexate or leflunomide naïve
Disease duration less than or equal to 2 years from diagnosis

Exclusion Criteria

History of acute inflammatory joint disease of different origin from rheumatoid arthritis, cancer, lymphoma, leukemia or lymphoproliferative disease, active TB, HIV
Previously received anti-TNF therapy anti-IL-6 receptor antibody, CTLA4-Ig, anti-CD20 antibody, cyclophosphamide, cyclosporine, azathioprine, or tacrolimus
Joint surgery involving joints to be assessed within 8 weeks prior to Screening

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

주 목적: 치료
할당: 무작위
중재 모델: 병렬 할당
마스킹: 네 배로

팔의 수

무기와 개입

참가자 그룹 / 팔	개입 / 치료
위약 비교기: DB Placebo Participants received double-blind placebo administered subcutaneously (SC) every other week (eow) for up to 26 weeks. Participants also received concomitant methotrexate 6 to 8 mg administered orally weekly.	의약품: Double-blind Placebo Double-blind adalimumab-matching placebo administered subcutaneously (SC)every other week (eow) 다른 이름들: 위약
실험적: DB adalimumab Participants received double-blind adalimumab 40 mg administered subcutaneously (SC) every other week (eow) for up to 26 weeks. Participants also received concomitant methotrexate 6 to 8 mg administered orally weekly.	생물학적: Double-blind adalimumab Double-blind adalimumab 40 mg administered subcutaneously (SC) every other week (eow) 다른 이름들: ABT-D2E7, 아달리무맙, 휴미라
실험적: DB Adalimumab/OL Adalimumab Participants received double-blind adalimumab administered subcutaneously (SC) every other week (eow) for 26 weeks followed by open-label adalimumab 40 mg SC eow for up to 26 weeks. Participants also received concomitant methotrexate 6 to 8 mg administered orally weekly.	생물학적: Double-blind adalimumab Double-blind adalimumab 40 mg administered subcutaneously (SC) every other week (eow) 다른 이름들: ABT-D2E7, 아달리무맙, 휴미라 생물학적: Open-label Adalimumab Open-label adalimumab 40 mg administered subcutaneously (SC) every other week (eow) after completion of the first 26 weeks in the study 다른 이름들: 아달리무맙 ABT-D2E7 휴미라
실험적: DB Placebo/OL Adalimumab Participants received double-blind placebo administered subcutaneously (SC) every other week (eow) for 26 weeks followed by open-label adalimumab 40 mg SC eow for up to 26 weeks. Participants received concomitant methotrexate 6 to 8 mg administered orally weekly.	의약품: Double-blind Placebo Double-blind adalimumab-matching placebo administered subcutaneously (SC)every other week (eow) 다른 이름들: 위약 생물학적: Open-label Adalimumab Open-label adalimumab 40 mg administered subcutaneously (SC) every other week (eow) after completion of the first 26 weeks in the study 다른 이름들: 아달리무맙 ABT-D2E7 휴미라
실험적: DB Adalimumab/RE OL Adalimumab Participants received double-blind adalimumab 40 mg administered subcutaneously (SC) every other week (eow) and then open-label adalimumab 40 mg SC eow as rescue treatment (as eligible at Week 12 or after) to complete 26 weeks, followed by open-label adalimumab 40 mg SC eow for up to 26 weeks. Participants received concomitant methotrexate 6 to 8 mg administered orally weekly.	생물학적: Double-blind adalimumab Double-blind adalimumab 40 mg administered subcutaneously (SC) every other week (eow) 다른 이름들: ABT-D2E7, 아달리무맙, 휴미라 생물학적: Open-label Adalimumab Open-label adalimumab 40 mg administered subcutaneously (SC) every other week (eow) after completion of the first 26 weeks in the study 다른 이름들: 아달리무맙 ABT-D2E7 휴미라 생물학적: Open-labelAdalimumabRescue Open-label adalimumab 40 mg administered subcutaneously (SC) every other week (eow) as rescue treatment to complete the first 26 weeks in the study- dependent on participant eligibility (increase in disease activity), applies to Weeks 12 to 26 다른 이름들: 아달리무맙 ABT-D2E7 휴미라
실험적: DB Placebo/RE OL Adalimumab Participants received double-blind placebo administered subcutaneously (SC) every other week (eow) and then open-label adalimumab 40 mg SC eow as rescue treatment (as eligible at Week 12 or after) to complete 26 weeks, followed by open-label adalimumab 40 mg SC eow for up to 26 weeks. Participants received concomitant methotrexate 6 to 8 mg administered orally weekly.	의약품: Double-blind Placebo Double-blind adalimumab-matching placebo administered subcutaneously (SC)every other week (eow) 다른 이름들: 위약 생물학적: Open-label Adalimumab Open-label adalimumab 40 mg administered subcutaneously (SC) every other week (eow) after completion of the first 26 weeks in the study 다른 이름들: 아달리무맙 ABT-D2E7 휴미라 생물학적: Open-labelAdalimumabRescue Open-label adalimumab 40 mg administered subcutaneously (SC) every other week (eow) as rescue treatment to complete the first 26 weeks in the study- dependent on participant eligibility (increase in disease activity), applies to Weeks 12 to 26 다른 이름들: 아달리무맙 ABT-D2E7 휴미라

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정	측정값 설명	기간
Change From Baseline in Modified Total Sharp X-Ray Score at Week 26 기간: Baseline, Week 26	Modified Total Sharp Score (mTSS) is a measure of joint health, used in evaluation of inhibition of radiographic progression of disease. Digitized X-rays of hands and feet were obtained then scored in a blinded manner: for erosions (0 [no damage] to 5 [complete collapse or total destruction of joint]) and for joint space narrowing (0 [no damage] to 4 [complete luxation of joint]). Scores were added, giving total mTSS (0 [normal] to 380 [maximal disease]). Large positive change in mTSS indicates disease progression; small positive/no change indicates slowing/halting of disease progression.	Baseline, Week 26

2차 결과 측정

결과 측정	측정값 설명	기간
Number of Participants Meeting ACR20 Response Criteria at Week 26 (ACR: American College of Rheumatology) 기간: Week 26	Patients were ACR20 responders if they had: >= 20% improvement in both tender joint count (68 joints) and in swollen joint count (66 joints) plus >=20% improvement in at least 3 of the 5 remaining ACR core measures: patient's assessment of pain; patient's global assessment of disease activity; physician's global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire [HAQ]); and acute phase reactant C-reactive protein. Patients who discontinued or switched to open-label adalimumab prior to Week 26 were considered non-responders.	Week 26
Number of Participants Meeting ACR50 Response Criteria at Week 26 (ACR: American College of Rheumatology) 기간: Week 26	Patients were ACR50 responders if they had: >= 50% improvement in both tender joint count (68 joints) and in swollen joint count (66 joints) plus >=50% improvement in at least 3 of the 5 remaining ACR core measures: patient's assessment of pain; patient's global assessment of disease activity; physician's global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire [HAQ]); and acute phase reactant C-reactive protein. Patients who discontinued or switched to open-label adalimumab prior to Week 26 were considered non-responders.	Week 26
Number of Participants Meeting ACR70 Response Criteria at Week 26 (ACR: American College of Rheumatology) 기간: Week 26	Patients were ACR70 responders if they had: >= 70% improvement in both tender joint count (68 joints) and in swollen joint count (66 joints) plus >=70% improvement in at least 3 of the 5 remaining ACR core measures: patient's assessment of pain; patient's global assessment of disease activity; physician's global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire [HAQ]); and acute phase reactant C-reactive protein. Patients who discontinued or switched to open-label adalimumab prior to Week 26 were considered non-responders.	Week 26
Change From Baseline in Disease Activity Score (DAS28[ESR]) at Week 26 기간: Baseline, Week 26	Disease Activity Score (DAS28) is a combined index used to measure disease activity in patients with rheumatoid arthritis. Calculation of the DAS28 score used the tender joint count (28 joints), swollen joint count (28 joints), patient's global assessment of disease activity, and the erythrocyte sedimentation rate. DAS28(ESR) scores range from 0 (no disease activity) to 9 (maximal disease activity); decrease is indicative of improvement in disease activity.	Baseline, Week 26
Number of Participants Achieving Clinical Remission, Defined by Disease Activity Score (DAS28[ESR]) <2.6, at Week 26 기간: Week 26	Disease Activity Score (DAS28) is a combined index used to measure disease activity in patients with rheumatoid arthritis. Calculation of the DAS28 score used the tender joint count (28 joints), swollen joint count (28 joints), patient's global assessment of disease activity, and the erythrocyte sedimentation rate. DAS28(ESR) scores range from 0 (no disease activity) to 9 (maximal disease activity); decrease is indicative of improvement in disease activity. DAS28(ESR) score <2.6 was defined as clinical remission of disease.	Week 26
Number of Participants Who Reported Any Adverse Event (Serious or Non-serious) on Double-blind Study Drug Through Week 26 기간: Through Week 26	Adverse events were collected at designated study visits for all participants who were randomized and received at least 1 dose of study drug. The number of participants who experienced any adverse event (serious or non-serious) while receiving double-blind study drug is summarized. See the Reported Adverse Event section for details.	Through Week 26
Change From Baseline in Modified Total Sharp X-Ray Score at Week 52 기간: Baseline, Week 52	Modified Total Sharp Score (mTSS) is a measure of joint health, used in evaluation of inhibition of radiographic progression of disease. Digitized X-rays of hands and feet were obtained then scored in a blinded manner: for erosions (0 [no damage] to 5 [complete collapse or total destruction of joint]) and for joint space narrowing (0 [no damage] to 4 [complete luxation of joint]). Scores were added, giving total mTSS score (0 [normal] to 380 [maximal disease]). Large positive change in mTSS indicates diseae progression; small positive/no change indicates slowing/halting of disease progression.	Baseline, Week 52
Number of Participants Meeting ACR20 Response Criteria at Week 52 (ACR: American College of Rheumatology) 기간: Week 52	Patients were ACR20 responders if they had: >=20% improvement in both tender joint count (68 joints) and in swollen joint count (66 joints) plus >=20% improvement in at least 3 of the 5 remaining ACR core measures: patient's assessment of pain; patient's global assessment of disease activity; physician's global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire (HAQ); and acute phase reactant C-reactive protein.	Week 52
Number of Participants Meeting ACR50 Response Criteria at Week 52 (ACR: American College of Rheumatology) 기간: Week 52	Patients were ACR50 responders if they had: >=50% improvement in both tender joint count (68 joints) and in swollen joint count (66 joints) plus >=50% improvement in at least 3 of the 5 remaining ACR core measures: patient's assessment of pain; patient's global assessment of disease activity; physician's global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire (HAQ); and acute phase reactant C-reactive protein.	Week 52
Number of Participants Meeting ACR70 Response Criteria at Week 52 (ACR: American College of Rheumatology) 기간: Week 52	Patients were ACR70 responders if they had: >=70% improvement in both tender joint count (68 joints) and in swollen joint count (66 joints) plus >=70% improvement in at least 3 of the 5 remaining ACR core measures: patient's assessment of pain; patient's global assessment of disease activity; physician's global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire (HAQ); and acute phase reactant C-reactive protein.	Week 52
Change From Baseline in Disease Activity Score (DAS28[ESR]) at Week 52 기간: Baseline, Week 52	Disease Activity Score (DAS28) is a combined index used to measure disease activity in patients with rheumatoid arthritis. Calculation of the DAS28 score used the tender joint count (28 joints), swollen joint count (28 joints), patient's global assessment of disease activity, and the erythrocyte sedimentation rate. DAS28(ESR) scores range from 0 (no disease activity) to 9 (maximal disease activity); decrease is indicative of improvement in disease activity.	Baseline, Week 52
Number of Participants Achieving Clinical Remission, Defined by Disease Activity Score (DAS28[ESR]) <2.6, at Week 52 기간: Week 52	Disease Activity Score (DAS28) is a combined index used to measure disease activity in patients with rheumatoid arthritis. Calculation of the DAS28 score used the tender joint count (28 joints), swollen joint count (28 joints), patient's global assessment of disease activity, and the erythrocyte sedimentation rate. DAS28(ESR) scores range from 0 (no disease activity) to 9 (maximal disease activity); decrease is indicative of improvement in disease activity. DAS28(ESR) score <2.6 was defined as clinical remission of disease.	Week 52
Number of Participants Who Reported Any Adverse Event (Serious or Non-serious) While Receiving Adalimumab Through Week 52 기간: Through Week 52	Adverse events were collected at designated study visits for all participants who were randomized and received at least 1 dose of adalimumab. The number of participants who experienced any adverse event (serious or non-serious) while receiving any adalimumab during the study (double-blind adalimumab and/or open-label) is summarized. See the Reported Adverse Event section for details.	Through Week 52

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

Abbott

협력자

Eisai Co., Ltd.

수사관

연구 책임자: Hiroshi Ukai, BS, Abbott Japan Co.,Ltd

간행물 및 유용한 링크

연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.

일반 간행물

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작

2009년 3월 1일

기본 완료 (실제)

2011년 3월 1일

연구 완료 (실제)

2011년 8월 1일

연구 등록 날짜

최초 제출

2009년 3월 26일

QC 기준을 충족하는 최초 제출

2009년 3월 26일

처음 게시됨 (추정)

2009년 3월 27일

연구 기록 업데이트

마지막 업데이트 게시됨 (추정)

2012년 8월 7일

QC 기준을 충족하는 마지막 업데이트 제출

2012년 8월 1일

마지막으로 확인됨

2012년 8월 1일

추가 정보

이 연구와 관련된 용어

키워드

류마티스 관절염

추가 관련 MeSH 약관

기타 연구 ID 번호

M06-859

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

Double-blind Placebo에 대한 임상 시험

Postgraduate Institute of Dental Sciences Rohtak

모병

RT1 치은 후퇴에서 NORD Flap 대 상피하 결합 조직 이식편에 의한 치근피복 결과 비교 (Recession type)

치은 후퇴

인도
Izmir Katip Celebi University
Ege University

완전한

웹 기반 Double Eye Control 프로그램 사용이 투약 오류에 미치는 영향

주요 제목(설명자) 용어

칠면조
Rajeev Chaudhry
Children's Healthcare of Atlanta

종료됨

유치 Double-J 요관 스텐트와 신우 성형술을 위한 외부 수정-Salle 스텐트

요관 골반 접합부 폐쇄

미국
Evolucare Technologies
Assistance Publique - Hôpitaux de Paris; Slb Pharma; BPIfrance

모병

안구 질환의 자동 스크리닝을 위한 OphtAI 진단 성능 검증 (OPHTAI-EVAL)

녹내장 | 연령 관련 황반 변성 | 당뇨망막병증 | 당뇨병성 황반 부종 | 연령 관련 황반병증

프랑스
University of Sao Paulo

알려지지 않은

피부 화상 및 삶의 질 회복을 위한 정전용량 장에 의한 전기 자극의 사용

화상 | 상처 치유

브라질
Rabin Medical Center

완전한

튜브리스 대 표준 상부 기둥 경피적 신장절개술

흉막 삼출액

이스라엘
Regional Cardiology Center, The Copper Health Centre...
Department of Cardiology, Provincial Specialized Hospital in Legnica, 59-200 Legnica,...

모병

Lower Silesia Culotte Bifurcation Registry (LSCBR). (LSCBR)

안전성 문제 | 효능, 자기

폴란드
University of Louisville

빼는

기존의 Double-J 스텐트와 비교한 요관내 스텐트의 이동.

비뇨기과 질환 | 비뇨기과 시스템 절차의 합병증
University of Florida
University of Sao Paulo

완전한

구개열 수술 및 언어 발달

구개열 | 구순 구개열

미국, 브라질
Peking Union Medical College Hospital

알려지지 않은

젖산나트륨 링거 주사로 패혈성 쇼크 환자 소생

젖산염 | 패혈성 쇼크를 동반한 중증 패혈증

A Study of Adalimumab in Japanese Subjects With Rheumatoid Arthritis

A Phase 3 Multi-Center, Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study Comparing Adalimumab and Placebo in Adult Japanese Subjects With Rheumatoid Arthritis

연구 개요

상태

정황

개입 / 치료

상세 설명

연구 유형

등록 (실제)

단계

연락처 및 위치

연구 장소

참여기준

자격 기준

공부할 수 있는 나이

건강한 자원 봉사자를 받아들입니다

연구 대상 성별

설명

공부 계획

연구는 어떻게 설계됩니까?

디자인 세부사항

팔의 수

무기와 개입

참가자 그룹 / 팔

개입 / 치료

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정

측정값 설명

기간

2차 결과 측정

결과 측정

측정값 설명

기간

공동 작업자 및 조사자

스폰서

협력자

수사관

간행물 및 유용한 링크

일반 간행물

연구 기록 날짜

연구 주요 날짜

연구 시작

기본 완료 (실제)

연구 완료 (실제)

연구 등록 날짜

최초 제출

QC 기준을 충족하는 최초 제출

처음 게시됨 (추정)

연구 기록 업데이트

마지막 업데이트 게시됨 (추정)

QC 기준을 충족하는 마지막 업데이트 제출

마지막으로 확인됨

추가 정보

이 연구와 관련된 용어

키워드

추가 관련 MeSH 약관

기타 연구 ID 번호

Double-blind Placebo에 대한 임상 시험

유사한 임상시험 검색

스폰서 및 공동 작업자

건강 상태

약물 개입

CROs by country

CROs in Equatorial Guinea

정황

희귀 질병

약물 개입

식이 보충제

스폰서 / 협력자

위치